Beijing Chunlizhengda Medical Instruments Co., Ltd.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE100001TP1
HKD
15.38
-0.07 (-0.45%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationQuarterly Results
Results Snapshot
YoYQoQ
Figures in Million
Consolidate Quarterly Results
Mar'25
Dec'24
Sep'24
Jun'24
Mar'24
Dec'23
Sep'23
Net Sales
243.65
319.96
137.63
168.15
239.37
444.58
269.63
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
243.65
319.96
137.63
168.15
239.37
444.58
269.63
Raw Material Cost
81.87
128.59
58.53
59.90
68.89
114.89
96.19
Purchase of Finished goods
0.00
0.00
0.00
0.00
0.00
0.00
0.00
(Increase) / Decrease In Stocks
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Employee Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
0.00
0.02
0.00
0.03
0.00
0.04
0.01
Selling and Distribution Expenses
75.15
92.17
66.04
65.21
80.58
171.47
79.88
Other Expenses
2.88
3.25
3.12
3.18
3.46
4.21
3.94
Total Expenditure (Excl Depreciation)
185.78
253.24
155.73
156.89
184.03
328.55
215.47
Operating Profit (PBDIT) excl Other Income
57.9
66.7
-18.1
11.299999999999999
55.300000000000004
116
54.2
Other Income
10.21
26.79
2.71
15.56
8.65
19.16
4.87
Operating Profit (PBDIT)
67.23
77.44
-9.58
31.27
74.10
126.22
69.00
Interest
0.00
0.02
0.00
0.03
0.00
0.04
0.01
Exceptional Items
1.72
3.63
1.53
3.55
1.50
2.74
2.90
Gross Profit (PBDT)
161.78
191.37
79.10
108.25
170.48
329.68
173.44
Depreciation
0.00
10.29
10.35
10.07
10.15
9.99
9.98
Profit Before Tax
68.95
70.76
-18.40
24.73
65.46
118.94
61.91
Tax
6.90
1.93
1.14
-1.02
5.50
13.71
3.08
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
62.09
69.04
-19.45
25.72
60.05
105.08
58.89
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
62.09
69.04
-19.45
25.72
60.05
105.08
58.89
Share in Profit of Associates
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Minority Interest
-0.04
-0.20
-0.08
0.03
-0.10
0.15
-0.05
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
62.04
68.84
-19.53
25.75
59.95
105.22
58.84
Equity Capital
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Face Value
1.07
1.06
1.11
1.07
1.08
1.1
1.07
Reserves
3,087.76
3,000.97
3,094.12
3,027.57
3,175.72
3,168.11
2,981.17
Earnings per share (EPS)
0.16
0.18
-0.05
0.07
0.16
0.27
0.15
Diluted Earnings per share
0.16
0.18
-0.05
0.07
0.16
0.27
0.15
Operating Profit Margin (Excl OI)
23.4%
12.62%
-16.45%
3.36%
23.11%
21.84%
20.08%
Gross Profit Margin
28.3%
25.33%
-5.84%
20.69%
31.58%
29.0%
26.66%
PAT Margin
25.48%
21.58%
-14.13%
15.3%
25.09%
23.63%
21.84%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Quarterly Analysis Highlights - YoY
stock-summary

Net Sales

YoY Growth in quarter ended Mar 2025 is 1.75% vs -14.65% in Mar 2024

stock-summary

Consolidate Net Profit

YoY Growth in quarter ended Mar 2025 is 3.33% vs -6.25% in Mar 2024

stock-summary

Operating Profit (PBDIT) excl Other Income

YoY Growth in quarter ended Mar 2025 is -12.98% vs -7.49% in Mar 2024

stock-summary

Interest

No Interest in the last few periods

stock-summary

Operating Profit Margin (Excl OI)

YoY Growth in quarter ended Mar 2025 has improved from Mar 2024

Compare Quarterly Results Of Beijing Chunlizhengda Medical Instruments Co., Ltd. With
Markets Mojo
Figures in Million
Consolidate Quarterly Results
Markets Mojo
Markets Mojo
Change(HKD)
Change(%)
Net Sales
243.65
0
243.65
Other Operating Income
0.00
0.00
0.00
Total Operating income
243.65
0
243.65
Raw Material Cost
81.87
0
81.87
Purchase of Finished goods
0
0
0.00
(Increase) / Decrease In Stocks
0
0
0.00
Employee Cost
0.00
0
0.00
Power Cost
0
0
0.00
Manufacturing Expenses
0.00
0
0.00
Selling and Distribution Expenses
75.15
0
75.15
Other Expenses
2.88
0.00
2.88
Total Expenditure (Excl Depreciation)
185.78
0
185.78
Operating Profit (PBDIT) excl Other Income
57.86
0.00
57.86
Other Income
10.21
0
10.21
Operating Profit (PBDIT)
67.23
0
67.23
Interest
0.00
0
0.00
Exceptional Items
1.72
0
1.72
Gross Profit (PBDT)
161.78
0
161.78
Depreciation
0.00
0
0.00
Profit Before Tax
68.95
0
68.95
Tax
6.90
0
6.90
Provisions and contingencies
0
0
0.00
Profit After Tax
62.09
0
62.09
Extraordinary Items
0.00
0
0.00
Prior Period Expenses
0
0
0.00
Other Adjustments
0
0
0.00
Net Profit
62.09
0
62.09
Share in Profit of Associates
0
0
0.00
Minority Interest
-0.04
0
-0.04
Other related items
0.00
0.00
0.00
Consolidated Net Profit
62.04
0
62.04
Equity Capital
0
0
0.00
Face Value
1.07
0
0.00
Reserves
3,087.76
0
3,087.76
Earnings per share (EPS)
0.16
0
0.16
Diluted Earnings per share
0.16
0
0.16
Operating Profit Margin (Excl OI)
23.40%
0%
0.00
23.40%
Gross Profit Margin
28.30%
0%
0.00
28.30%
PAT Margin
25.48%
0%
0.00
25.48%
Public Share Holdings (%)
0%
0%
0.00
0.00%
Pledged Promotor Holding (%)
0%
0%
0.00
0.00%
Quarterly - Net Sales
Net Sales 24.36 Million
in Mar 2025

Figures in Million
stock-summary

QoQ Growth in quarter ended Mar 2025 is -23.88% vs 132.56% in Dec 2024

stock-summary

YoY Growth in quarter ended Mar 2025 is 1.75% vs -14.65% in Mar 2024

Quarterly - Consolidate Net Profit
Consolidate Net Profit 6.20 Million
in Mar 2025

Figures in Million
stock-summary

QoQ Growth in quarter ended Mar 2025 is -9.88% vs 452.82% in Dec 2024

stock-summary

YoY Growth in quarter ended Mar 2025 is 3.33% vs -6.25% in Mar 2024

Quarterly - Operating Profit (PBDIT)
Operating Profit (PBDIT) 5.70 Million
in Mar 2025

Figures in Million
stock-summary

QoQ Growth in quarter ended Mar 2025 is 12.43% vs 512.20% in Dec 2024

stock-summary

YoY Growth in quarter ended Mar 2025 is -12.98% vs -7.49% in Mar 2024

Quarterly - Interest
Markets Mojo
No Interest in the last few periods
Quarterly - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 23.40%
in Mar 2025

Figures in %
stock-summary

QoQ Growth in quarter ended Mar 2025 has improved from Dec 2024

stock-summary

YoY Growth in quarter ended Mar 2025 has improved from Mar 2024